| Literature DB >> 31818951 |
Else Driehuis1,2, Arne van Hoeck1,3, Kat Moore4, Sigrid Kolders1,2, Hayley E Francies5, M Can Gulersonmez6, Edwin C A Stigter6, Boudewijn Burgering6, Veerle Geurts1,2, Ana Gracanin7, Gergana Bounova4, Folkert H Morsink8, Robert Vries7, Sylvia Boj7, Johan van Es1,2, G Johan A Offerhaus8, Onno Kranenburg9, Mathew J Garnett5, Lodewyk Wessels4, Edwin Cuppen1,3,10,11, Lodewijk A A Brosens8, Hans Clevers12,2,13.
Abstract
We report the derivation of 30 patient-derived organoid lines (PDOs) from tumors arising in the pancreas and distal bile duct. PDOs recapitulate tumor histology and contain genetic alterations typical of pancreatic cancer. In vitro testing of a panel of 76 therapeutic agents revealed sensitivities currently not exploited in the clinic, and underscores the importance of personalized approaches for effective cancer treatment. The PRMT5 inhibitor EZP015556, shown to target MTAP (a gene commonly lost in pancreatic cancer)-negative tumors, was validated as such, but also appeared to constitute an effective therapy for a subset of MTAP-positive tumors. Taken together, the work presented here provides a platform to identify novel therapeutics to target pancreatic tumor cells using PDOs.Entities:
Keywords: biobank; cancer; organoids; pancreatic cancer; personalized medicine
Year: 2019 PMID： 31818951 PMCID： PMC6936689 DOI： 10.1073/pnas.1911273116
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205